ClinicalTrials.gg
Not yet recruitingNCT07944885Updated Nov 18, 2026

First-in-human Study of SAR448632 in Healthy Adult Participants

A Phase 1 interventional study of Placebo and SAR448632 in Healthy Volunteer, sponsored by Sanofi. Not yet recruiting. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Sanofi · Phase 1, Interventional, and Treatment

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a randomized, first-in-human, placebo-controlled, double-blind, Phase 1 study to assess the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics and target engagement after sequential single ascending doses of SAR448632 in healthy adult male and female participants.

02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

Sanofi is the lead sponsor of 1,560 studies on the registry; 91 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination).
  • Body weight between 45.0 and 95.0 kg, inclusive; (BMI) between 18.5 and 27.9 kg/m², inclusive.
  • use by male or female participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion criteria

Exclusion Criteria:

  • Any history or presence of cardiovascular, pulmonary, gastrointestinal, dermatologic, hepatic, renal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynecologic, or infectious disease, or signs of acute illness.
  • Frequent headaches and/or migraine, recurrent nausea and/or vomiting (for vomiting only: more than twice a month).
  • Any volume of blood donation, or blood loss >200 mL, within 2 months before inclusion.
  • History or presence of drug or alcohol abuse.
  • Regular smoking regularly more than 5 cigarettes or equivalent in nicotine per week, unable to stop smoking (occasional smoker can be enrolled).
  • Symptomatic herpes zoster within 3 months prior to Screening.
  • History of recurrent oral or genital herpes.
  • Any history of active or latent Tuberculosis (TB).
  • Participants with fever (temperature >38℃), active infection requiring systemic treatment at screening, chronic or recurrent infections requiring systemic treatment with antibiotics, antivirals, or antifungals within 4 weeks prior to screening, or any history of chronic or recurrent infections suggesting underlying immune dysfunction, as deemed unacceptable by the Investigator.
  • Any biologics (antibody or its derivatives) given within 4 months before inclusion.
  • Vaccination: Receipt of live (attenuated) vaccines within 3 months and/or non- within 4 weeks prior to randomization on Day 1, or planned to receive these vaccines at any time throughout the study.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    SAR448632

    Participants will receive a single dose of SAR448632 by SC injection or infusion on Day 1 only.

    Drug: SAR448632

  • Placebo comparator
    Placebo

    The placebo administration will match the dosing planned for SAR448632

    Drug: Placebo

Interventions

  • DrugPlacebo

    Administration method will match SAR448632

  • DrugSAR448632

    Route of administration: SC injection or infusion

06

What researchers measure

Primary outcomes

  1. Number of participants with assessment of Adverse Events (AEs) / Treatment-Emergent Adverse Events (TEAEs), including Injection Site Reactions (ISRs)

    Assessment of AEs/TEAEs including ISRs.

    Time frame: Baseline to day 113

  2. Number of participants with potentially clinically significant abnormalities in clinical laboratory evaluation; Vital signs; 12-lead Electrocardiogram.

    Clinical laboratory evaluations (hematology, biochemistry, coagulation, urinalysis); Vital signs; 12-lead ECG (heart rate, PR, QRS, QT, QTcF).

    Time frame: Baseline to day 113

Secondary outcomes

  1. Maximum observed plasma concentration (Cmax )

    Time frame: Baseline to day 99

  2. Time to reach maximum observed plasma concentration (tmax )

    Time frame: Baseline to day 99

  3. Area under the plasma concentration-time curve (AUC)

    Time frame: Baseline to day 99

  4. Area under the plasma concentration-time curve from time zero to the last quantifiable concentration (AUC last ).

    Time frame: Baseline to day 99

  5. Incidence of participants with presence of Anti-Drug Antibody (ADA) against SAR448632.

    Time frame: Baseline to day 99

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Aug 2027, 8 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Aug 15, 2027
CompletionEst.
Aug 15, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07944885
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Aug 15, 2027 (estimated)
Completion
Aug 15, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Trial Transparency email recommended (Toll free for US & Canada)
Contact
Contact-US@sanofi.com
800-633-1610 ext. option 6

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion